French drugmaker Sanofi (Euronext: SAN) has reported net sales for the second quarter of 2023 of $9.9 billion euros ($10.9 billion), a 1.5% fall, with net income of 1.4 billion euros and earnings per share (EPS) of 1.15 euros.
Beating many analysts’ expectations, the results have encouraged the firm to raise its outlook for the year.
Sanofi now expects 2023 EPS to grow at a mid single-digit rate, an outcome which includes an approximately 400 million-euro boost from better-than-expected vaccines sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze